【24h】

Circulating Microparticles

机译:循环微粒

获取原文
           

摘要

Although the presence of subcellular procoagulant particles in highly centrifuged plasma has been known for many years, it was not until 1967 that shed membrane procoagulant fragments from activated platelets were described by Wolf 1 as “platelet dust.” Since then, numerous studies have reported the in vitro release of vesicles from activated or apoptotic cells and their presence in human plasma. Among the different membrane vesicles that cells could release, “microparticles” (MPs) usually refer to those >100 nm in diameter (Figure 1) and derived from the plasma membrane. Smaller vesicles (40 to 100 nm) originating from the endoplasmic membranes are described as “exosomes,” and larger particles (>1.5 μm) containing nuclear material are best known as “apoptotic bodies.”2–4 Both MPs and apoptotic bodies externalize the anionic phospholipid phosphatidylserine, which plays a crucial role in the activation of both coagulation and complement cascades and supports the binding and activity of secreted phospholipase A2. Figure 1. Electron microscopy of circulating MPs from patients with acute coronary syndrome (courtesy of Drs Z. Mallat and M. Wassef).This brief review summarizes the mechanisms leading to the formation and release of MPs, as well as the different approaches to detect their cellular origin in human plasma. This article also discusses the significance of circulating MPs of endothelial origin as both a marker and a trigger of endothelial dysfunction in cardiovascular diseases and the possible prognostic value of plasma MPs to assess cardiovascular risk.The current knowledge on MP formation derives mainly from experiments on isolated or cultured cells showing that both cell activation and cell apoptosis can lead to MP release. However, in vivo mechanisms involved in MP formation and shedding remain mostly unknown.The initial step in MP formation requires plasma membrane budding, leading to the formation of membrane blebs. This step …
机译:尽管高度离心的血浆中亚细胞促凝剂颗粒的存在已为人所知,但直到1967年,从活化的血小板中脱落的膜促凝剂碎片才被Wolf 1描述为“血小板尘埃”。从那时起,许多研究报告了从活化或凋亡细胞中体外释放囊泡及其在人血浆中的存在。在细胞可以释放的不同膜囊中,“微粒”(MPs)通常是指直径大于100 nm的微粒(图1),并来源于质膜。源自内质膜的较小囊泡(40至100 nm)被描述为“外泌体”,而含有核物质的较大颗粒(> 1.5μm)被称为“凋亡小体”。2-4MP和凋亡小体都将核小体外部化。阴离子磷脂磷脂酰丝氨酸,在凝血和补体级联的激活中都起着关键作用,并支持分泌的磷脂酶A2的结合和活性。图1.急性冠脉综合征患者循环MP的电子显微镜检查(由Dr. Z. Mallat和M. Wassef提供)。本简要概述总结了导致MP形成和释放的机制,以及不同的检测方法它们的细胞起源于人类血浆。本文还讨论了循环内皮源性MPs在心血管疾病中作为内皮功能障碍的标志物和触发物的意义以及血浆MPs评估心血管风险的可能预后价值。目前关于MP形成的知识主要来自于孤立的实验。或培养的细胞,表明细胞活化和细胞凋亡均可导致MP释放。然而,体内参与MP形成和脱落的机制仍然未知.MP形成的初始步骤需要质膜发芽,从而导致膜泡的形成。这一步...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号